Navigation Links
Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme
Date:12/7/2007

nd safety of the addition of CDX-110 vaccine to standard of care, versus standard of care alone. Celldex has currently enlisted 18 clinical centers throughout the United States, and also recently received approval from Health Canada to open enrollment in Canada. Furthermore, The National Cancer Institute (NCI) has agreed to collaborate with Celldex in expanded clinical development of CDX-110 under a Clinical Trials Agreement.

"Obtaining orphan designation for CDX-110 is an important milestone for Celldex," said Thomas Davis, M.D., Chief Medical Officer of Celldex Therapeutics. "Approval to expand clinical research into Canada and the scientific and clinical collaboration from the National Cancer Institute all promote our ability to fully explore the promise of CDX-110."

About CDX-110

CDX-110 is an investigational immunotherapy that targets the tumor specific molecule EGFRvIII, a functional variant of the epidermal growth factor receptor (EGFR), which is a protein that has been well validated as a target for cancer therapy. This particular variant, EGFRvIII occurs in about 40 percent of Glioblastoma Multiforme (GBM) patients. It was discovered in a collaborative effort between Dr. Bert Vogelstein and Dr Albert Wong at Johns Hopkins University and Dr. Darell Bigner at Duke University. Unlike EGFR, EGFRvIII is not present in normal tissues, suggesting this target will enable the development of a tumor-specific therapy for cancer patients. Furthermore, EGFRvIII is a transforming oncogene that can directly contribute to cancer cell growth. While originally discovered in GBM, the most common and aggressive form of brain cancer, the expression of EGFRvIII has also been observed in various other cancers such as breast, ovarian, metastatic prostate, colorectal, and head & neck cancers. Celldex has exclusive rights to EGFRvIII vaccines and is pursuing the development of CDX-110 for GBM therapy, as well as in other cancers through additional clinical studi
'/>"/>

SOURCE Celldex Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... , October 31, 2014 ... Corporation (NASDAQ: CELG ), Bristol-Myers Squibb Co. ... UNH ), Sanofi SA (NYSE: ... members receive these notes ahead of publication. To reserve ... . , ,-- ,Celgene Corporation Research Reports ,On October ...
(Date:10/31/2014)... , November 3, 2014 ... men with BPH to discuss "male orgasmic dysfunction" with ... ability to treat prostate symptoms while preserving sexual function ... welcomes the publication of a paper in the British ... from enlarged prostate to discuss with their doctors the ...
(Date:10/31/2014)... , Oct. 30, 2014 Migranade, Inc. announced ... be available to the 36 million U.S. migraine sufferers ... technology that targets the actual cause of migraines and ... pain and not the source Migranade is assured to ... MIGRANADE Migraine Relief is available at http://www.migranade.com ...
Breaking Medicine Technology:Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 2Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 3Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 4Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 5Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 6Sexual Dysfunction No Longer Inevitable When Treating Enlarged Prostate 2Game Changing Migraine Medication To Be Available November 2014 2
... MYSTIC, Conn., Aug. 17 Amarin Corporation plc (Nasdaq: ... a focus on cardiovascular disease, today announced that Colin ... (CEO) and a member of the Company,s Board of ... responsible for driving forward the Company,s strategy to maximize ...
... - Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX ... care and gastroenterology markets, today announces financial results for the ... for full year 2010. Net Revenue:   ... was $10.7 million, up 9% from $9.8 million for the ...
Cached Medicine Technology:Amarin Corporation Appoints Colin W. Stewart as President and Chief Executive Officer 2Amarin Corporation Appoints Colin W. Stewart as President and Chief Executive Officer 3Amarin Corporation Appoints Colin W. Stewart as President and Chief Executive Officer 4Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results 2Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results 3Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results 4Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results 5Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results 6Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results 7Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results 8Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results 9Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results 10Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results 11Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results 12Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results 13
(Date:10/31/2014)... 31, 2014 Springboard Biodiesel, a ... small scale BioPro™ biodiesel processors, announced on Thursday ... improve the performance and efficiency of small-scale biodiesel ... trio will recover more than 99% of ... the glycerin by-product produced while making biodiesel. ...
(Date:10/31/2014)... The Memory Healer review published by DailyGossip.org reveals that the ... from Alzheimer's disease. , In fact, Alexander Lynch has ... His father pointed a gun and shot him during an ... of this method understood that he needed to do something ... is based on years of research. The author of the ...
(Date:10/31/2014)... At the start of 2014, numerous news ... monoxide poisoning in their homes. Now, as 2015 (and ... Missouri-based heating and cooling company is taking a more ... the home heating season with the assurance that their ... Nov. 1, 2014, E and Q Heating and Cooling ...
(Date:10/31/2014)... FRIDAY, Oct. 31, 2014 (HealthDay News) -- Surgery for ... on where in the United States you live, a ... will experience low back pain at some point in ... receive professional medical care for a spine problem," co-author ... & Clinical Practice, said in a college news release. ...
(Date:10/31/2014)... research suggests that insomnia is a major contributor to ... fatal injuries. The results underscore the importance of the ... Sleep Awareness Project. , Results show that the risk ... with the number of insomnia symptoms present. People with ... likely to die from a fatal injury than those ...
Breaking Medicine News(10 mins):Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 2Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 3Health News:"Memory Healer" Review Reveals a New Natural Remedy Guide for Managing Memory Loss 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 3Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Insomnia increases risk of motor vehicle deaths, other fatal injuries 2
... Crdentia Corp. (OTC Bulletin,Board: CRDT), a leading U.S. ... has been awarded an exclusive healthcare staffing,contract by ... Rock Raceway,is a new development project that includes ... single-family lots. High Rock Raceway has partnered ...
... the Campaign to Eliminate Drunk Driving, ST. LOUIS, ... -- a holiday that traditionally brings large numbers of ... supporters have,convened in St. Louis to kick off their ... and Suites Hotel 800 Washington Ave, St.,Louis, Mo. The ...
... reveals racial disparities, troublesome drug side effects , , THURSDAY, ... first annual Breast Cancer Symposium shed light on racial ... can affect survival, and how nagging side effects cause ... in San Francisco, is co-sponsored by the American Society ...
... First-year Results of Guiding Stars, ... System, SCARBOROUGH, Maine, Sept. 6 Consumer,selection of ... outpacing,selection of those that don,t in many aisles of ... faster -- according to data in the year,since the ...
... MYL ) today announced that Mylan Pharmaceuticals Inc. has ... for its,Abbreviated New Drug Application (ANDA) for Carvedilol Tablets, ... Carvedilol Tablets are the generic version of GlaxoSmithKline,s,Coreg(R) Tablets. ... the 12 months ending June 30, 2007, for the ...
... Sept. 5 Fairbank Farms, a national,ground beef ... Ground Round Beef Patties. The ground beef patties, ... purchased by consumers in New,England on Wednesday September ... an abundance of caution, the product has been ...
Cached Medicine News:Health News:Crdentia Selected by High Rock Raceway to Provide Healthcare Staffing Services 2Health News:Hundreds of MADD Supporters Meet in St. Louis on Sept. 6-8 2Health News:Hundreds of MADD Supporters Meet in St. Louis on Sept. 6-8 3Health News:Hundreds of MADD Supporters Meet in St. Louis on Sept. 6-8 4Health News:Hundreds of MADD Supporters Meet in St. Louis on Sept. 6-8 5Health News:Hundreds of MADD Supporters Meet in St. Louis on Sept. 6-8 6Health News:Studies Shed New Light on Breast Cancer, Treatment 2Health News:Studies Shed New Light on Breast Cancer, Treatment 3Health News:Grocery Shoppers Are Following Stars to More Nutritious Choices 2Health News:Grocery Shoppers Are Following Stars to More Nutritious Choices 3Health News:Grocery Shoppers Are Following Stars to More Nutritious Choices 4
...
...
...
EDM Lumbar Drainage Kit with and without Bioglide are fabricated of radiopaque (barium impregnated) silicone tubing, and are packaged with stainless steel stylets inserted in the lumen....
Medicine Products: